ArticleBMC infectious diseases2026
Seroprevalence and associated factors of Epstein-Barr virus among blood donors in Sana'a, Yemen.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Epstein-Barr virus (EBV) is a widely distributed oncogenic virus that is associated with various human malignancies and autoimmune disorders. There are no data about the prevalence of EBV among healthy individuals, particularly healthy blood donors. Therefore, this study aimed to assess the seroprevalence of EBV and associated risk factors among male blood donors in the Sana'a capital of Yemen.
methodsThis study was designed as a cross-sectional study and conducted among 200 healthy male blood donors who attended the blood donation centers over a period of one year, from June 2023 to May 2024.
resultsOf the 200 blood donors, 80% and 8% were positive for anti-EBV-IgG and anti-EBV-IgM, respectively. A higher rate of anti-EBV-IgG was reported at 100% and 80.7%, respectively, among those aged 50-55 years and married participants. Moreover, anti-EBV-IgM was more found among those aged 40-49 years and single participants (9.6% and 8.4%, respectively). Both anti-EBV-IgG and anti-EBV-IgM were higher among blood donors inhabiting an urban area. The majority of participants with seropositivity for anti-EBV-IgG experienced swelling of lymph nodes (93.6%), nasopharyngitis (96.4%), fever (80.3%), and fatigue (80.6%). Furthermore, the highest rates of anti-EBV IgG were found in participants who chewed Khat (80.9%), used tobacco dipping (shammah) (96.7%), received blood transfusions (81.1%), and had previous surgery (86.4%). However, only tobacco dipping (shammah) showed a statistically significant association with anti-EBV IgG seropositivity (P=0.007).
conclusionThe prevalence of EBV was remarkably high among the population included in the study, reflecting its widespread presence in Yemen, which potentially leads to significant clinical complications in patients with weakened immune systems. These findings emphasize the importance of ongoing epidemiological surveillance, improved routine screening procedures for EBV among blood donors, and strengthened health awareness and education programs to limit and prevent the spread of the virus. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.